US biopharmaceutical company AbbVie Inc on Tuesday said that it would buy Botox-maker Allergan PLC for about US$63 billion, moving to diversify its product line as the industry faces pressure on drug prices.
The deal, the latest large transaction in pharma, broadens the product offerings for AbbVie, which has relied heavily on sales of Humira, a drug to treat rheumatoid arthritis that faces rising competition from generics.
Combining operations would allow annual savings of at least US$2 billion through trimming duplicative research and development spending and cuts in sales and marketing spending, the companies said in a statement. The deal is expected to close early next year.
“This is a transformational transaction for both companies and achieves unique and complementary strategic objectives,” AbbVie CEO Richard Gonzalez said in a statement. “With our enhanced growth platform to fuel industry-leading growth, this strategy allows us to diversify AbbVie’s business while sustaining our focus on innovative science and the advancement of our industry-leading pipeline well into the future.”
Allergan, which is based in Ireland, is best known for Botox, which reduces face wrinkles. The company specializes in the areas of medical aesthetics, eye care, central nervous system and gastroenterology.
Allergan, which grew quickly earlier in this decade, has faced pressure from Wall Street, in part due to worries over the hit from patent expirations of eye medication Restasis. Some analysts have called for the firm to be broken up.
The companies would have a combined annual revenue of US$48 billion and a presence in 175 countries, the statement said.
“This acquisition creates compelling value for Allergan’s stakeholders, including our customers, patients and shareholders,” Allergan CEO Brent Saunders said.
The offer represents a 45 percent premium over Monday’s share price of Allergan, whose management recommended the operation to shareholders.
Shares of Allergan on Tuesday surged 25.4 percent to US$162.43, while AbbVie fell 16.3 percent to US$65.70.
AbbVie has faced questions over patent expirations for Humira, which accounted for more than 60 percent of its revenue of US$32.7 billion last year.
Allergan made more sense to buy than some smaller targets with promising drugs under development, because it “meets our strategic goal to reduce reliance on Humira and allows us to continue expanding our focus on high-innovation science throughout the next decade,” Abbvie said.
“Smaller bolt-on acquisitions provide opportunities for future growth, but also require significant research and development investment amid scientific and clinical uncertainty,” the company added.
A report from Moody’s Investors Service earlier this month predicted more mergers in the pharma industry, citing the effect of patent expirations and a 2017 US tax reform that eased the burden of companies that take on debt for acquisitions.
The report also pointed to stepped-up pressure on drug manufacturers within the healthcare industry on pricing, “as well as the public backlash associated with implementing large price increases.”
Among the rows of vibrators, rubber torsos and leather harnesses at a Chinese sex toys exhibition in Shanghai this weekend, the beginnings of an artificial intelligence (AI)-driven shift in the industry quietly pulsed. China manufactures about 70 percent of the world’s sex toys, most of it the “hardware” on display at the fair — whether that be technicolor tentacled dildos or hyper-realistic personalized silicone dolls. Yet smart toys have been rising in popularity for some time. Many major European and US brands already offer tech-enhanced products that can enable long-distance love, monitor well-being and even bring people one step closer to
Malaysia’s leader yesterday announced plans to build a massive semiconductor design park, aiming to boost the Southeast Asian nation’s role in the global chip industry. A prominent player in the semiconductor industry for decades, Malaysia accounts for an estimated 13 percent of global back-end manufacturing, according to German tech giant Bosch. Now it wants to go beyond production and emerge as a chip design powerhouse too, Malaysian Prime Minister Anwar Ibrahim said. “I am pleased to announce the largest IC (integrated circuit) Design Park in Southeast Asia, that will house world-class anchor tenants and collaborate with global companies such as Arm [Holdings PLC],”
Sales in the retail, and food and beverage sectors last month continued to rise, increasing 0.7 percent and 13.6 percent respectively from a year earlier, setting record highs for the month of March, the Ministry of Economic Affairs said yesterday. Sales in the wholesale sector also grew last month by 4.6 annually, mainly due to the business opportunities for emerging applications related to artificial intelligence (AI) and high-performance computing technologies, the ministry said in a report. The ministry forecast that retail, and food and beverage sales this month would retain their growth momentum as the former would benefit from Tomb Sweeping Day
Thousands of parents in Singapore are furious after a Cordlife Group Ltd (康盛人生集團), a major operator of cord blood banks in Asia, irreparably damaged their children’s samples through improper handling, with some now pursuing legal action. The ongoing case, one of the worst to hit the largely untested industry, has renewed concerns over companies marketing themselves to anxious parents with mostly unproven assurances. This has implications across the region, given Cordlife’s operations in Hong Kong, Macau, Indonesia, the Philippines and India. The parents paid for years to have their infants’ cord blood stored, with the understanding that the stem cells they contained